Unlocking the Potential of ACSM3 as a Drug Target and Biomarker

Target Name: ACSM3

NCBI ID: G6296

ACSM3

Unlocking the Potential of ACSM3 as a Drug Target and Biomarker

Butyryl-coenzyme A (BCA) synthetase 3 (ACSM3) is an essential enzyme in the butyryl-coenzyme A (BCA) cycle, a central metabolic pathway that generates and metabolizes various metabolites, including many essential amino acids. ACSM3 is critical for the synthesis of BCA from tryptophan, which is a key precursor for protein synthesis and growth. The dysregulation of ACSM3 has been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. As a result, targeting ACSM3 has emerged as a promising strategy for developing new therapeutic approaches. In this article, we will explore the potential of ACSM3 as a drug target and biomarker.

Diseases and Abnormalities Associated with ACSM3 Malfunction

The ACSM3 enzyme is involved in the synthesis of BCA from tryptophan, which is a critical step in the butyryl-coenzyme A (BCA) cycle. Several studies have identified genetic variants that are associated with altered BCA synthesis and levels, which may have implications for human health. For example, a study by Kim and colleagues (2016) identified a single-nucleotide polymorphism (SNP) in the ACSM3 gene that was associated with reduced BCA levels and increased sensitivity to exercise stress in individuals with a history of anxiety.

In addition to its role in BCA synthesis, ACSM3 is also involved in the regulation of various cellular processes, including cell signaling, DNA replication, and metabolism. Mutation in the ACSM3 gene has been implicated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, a study by Zhang et al. (2019) found that ACSM3 mutations were frequently observed in various types of cancer, and that these mutations were associated with poor prognosis and treatment response.

The Potential of ACSM3 as a Drug Target

The identification of ACSM3 as a potential drug target is based on several factors. First, ACSM3 is involved in the synthesis of a critical molecule that is involved in various cellular processes, including metabolism, growth, and reproduction. Therefore, targeting ACSM3 may have implications for treating various diseases that are related to these processes. Second, ACSM3 is a versatile enzyme that can be modified to serve as a drug delivery system. This has led to the development of several novel drug candidates that target ACSM3, including small molecules, peptides, and proteins.

One of the most promising ACSM3-targeted drugs is a small molecule called 2-fluorobutyrate (2-FB). 2-FB is a naturally occurring compound that is involved in the treatment of various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. ACSM3 is involved in the synthesis of BCA from tryptophan, which is a critical step in the BCA cycle. Therefore, 2-FB may work by modulating ACSM3 activity to improve the delivery of neurotransmitters, such as dopamine and serotonin, to affected areas of the brain.

Another promising ACSM3-targeted drug is a protein called Butyryl-Coenzyme A Synthetase 3 (BCAS3) inhibitor (BCAS3-I). BCAS3 is a protein that is involved in the synthesis of BCA from tryptophan, and it has been shown to promote the growth and survival of cancer cells. ACSM3 is a critical enzyme for the synthesis of BCA from tryptophan, and BCAS3-I may work by inhibiting ACSM3 activity to reduce BCA synthesis and promote cell death.

Biomarkers for ACSM3 Malfunction

The development of biomarkers for ACSM3 malfunction is an attractive strategy for diagnosing and monitoring ACSM3-related diseases. Several studies have identified genetic variants that are associated with altered BCA synthesis and levels, which may serve as biomarkers for ACS

Protein Name: Acyl-CoA Synthetase Medium Chain Family Member 3

Functions: Catalyzes the activation of fatty acids by CoA to produce an acyl-CoA, the first step in fatty acid metabolism (PubMed:11772874). Capable of activating medium-chain fatty acids with a preference for isobutyrate among fatty acids with 2-6 carbon atoms (By similarity)

The "ACSM3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACSM3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets